Derosa, Lisa

Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors

Bredon, M., Danne, C., Pham, H. P., Ruffié, P., Bessede, A., Rolhion, N., Creusot, L., Brot, L., Alonso, I., Langella, P., et al. (2024) · OncoImmunology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 74

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

Derosa, L., Routy, B., Kroemer, G., & Zitvogel, L. (2018) · OncoImmunology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 74

Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy

Elkrief, A., Méndez-Salazar, E. O., Maillou, J., Vanderbilt, C. M., Gogia, P., Desilets, A., Messaoudene, M., Kelly, D., Ladanyi, M., Hellmann, M. D., et al. (2024) · npj Precision Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 68

Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients

Chen, J., Levy, A., Tian, A.-L., Huang, X., Cai, G., Fidelle, M., Rauber, C., Ly, P., Pizzato, E., Sitterle, L., et al. (2025) · Cancer Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 67

Multifaceted modes of action of the anticancer probiotic Enterococcus hirae

Goubet, A.-G., Wheeler, R., Fluckiger, A., Qu, B., Lemaître, F., Iribarren, K., Mondragón, L., Tidjani Alou, M., Pizzato, E., Durand, S., et al. (2021) · Cell Death & Differentiation

Bacterial Cancer TherapyProbiotics and Fermented Foods

Cited by 54

Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

Alves Costa Silva, C., Piccinno, G., Suissa, D., Bourgin, M., Schreibelt, G., Durand, S., Birebent, R., Fidelle, M., Sow, C., Aprahamian, F., et al. (2024) · Nature Communications

Gut microbiota and healthCutaneous Melanoma Detection and Management

Cited by 33

Impact of the ONCOBIOME network in cancer microbiome research

Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., et al. (2025) · Nature Medicine

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 23

Gut Microbiota–Related Biomarkers in Immuno-Oncology

Silva, C. A. C., Fidelle, M., Almonte, A. A., Derosa, L., & Zitvogel, L. (2025) · Annual Review of Pharmacology and Toxicology

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 22

Surrogate markers of intestinal dysfunction associated with survival in advanced cancers

Birebent, R., Drubay, D., Alves Costa Silva, C., Marmorino, F., Vitali, G., Piccinno, G., Hurtado, Y., Bonato, A., Belluomini, L., Messaoudene, M., et al. (2025) · OncoImmunology

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 21

Benzodiazepines compromise the outcome of cancer immunotherapy

Montégut, L., Derosa, L., Messaoudene, M., Chen, H., Lambertucci, F., Routy, B., Zitvogel, L., Martins, I., & Kroemer, G. (2024) · OncoImmunology

Cancer Immunotherapy and BiomarkersCancer, Stress, Anesthesia, and Immune Response

Cited by 18

From mucosal infection to successful cancer immunotherapy

Goubet, A.-G., Rouanne, M., Derosa, L., Kroemer, G., & Zitvogel, L. (2023) · Nature Reviews Urology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 11

Antibiotics impair immunotherapy for urothelial cancer

Derosa, L., & Zitvogel, L. (2020) · Nature Reviews Urology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 9

Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer

Montégut, L., Rousseau, A., Ungolo, C., Derosa, L., Fidelle, M., Alves Costa Silva, C., Routy, B., Zitvogel, L., Besse, B., Pasolli, E., et al. (2025) · OncoImmunology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 8

Impact of microbiota specific circulating memory T cells in response to immunotherapy.

Gattazzo, F., Birebent, R., Lebhar, I., Xiberras, M., Marques, M., Reni, A., Flament, C., Bonato, A., Belluomini, L., Chanfreau-Paris, H., et al. (2024) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 4

Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.

Saliby, R. M., Machaalani, M., Zhong, C., Alves Costa Silva, C., Labaki, C., Saad, E., Steiner, C., Yekeduz, E., Eid, M., Daoud Khatoun, W., et al. (2025) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 2

Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines

Zitvogel, L., Carrier, A., Manghi, P., Silva, C. A. C., Lahmar, I., Birebent, R., Suissa, D., Laheurte, C., Schreibelt, G., Lemant, L., et al. (2025) · Research Square

Gut microbiota and healthImmune responses and vaccinations

Cited by 1